April 27 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE PRESENTS PRELIMINARY CLINICAL DATA ON CG-806 AT AACR VIRTUAL ANNUAL MEETING 2020
* APTOSE BIOSCIENCES - FIRST-IN-HUMAN TESTS OF CG-806 ARE BEING CARRIED OUT IN PHASE 1A/B CLINICAL STUDY
* APTOSE BIOSCIENCES - NO DRUG-RELATED SEVERE ADVERSE EVENTS OR DOSE-LIMITING TOXICITY HAVE BEEN OBSERVED IN PATIENTS TO DATE IN STUDY